XML 15 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 23,860,637 $ 19,136,472
Short-term investments 68,138,619 85,629,412
Accounts receivable 7,522,548 15,821,511
Accounts receivable from affiliated entity 1,189,300 748,355
Prepaid expenses and other current assets 4,914,764 1,749,059
Prepaid expenses and other current assets from affiliated entity 1,251,730 1,512,424
Total current assets 106,877,598 124,597,233
Fixed assets, net 15,017,992 9,025,446
Investment in affiliated entity - GeneOne 14,612,344 16,052,065
Investment in affiliated entity - PLS 3,339,802 3,777,510
Intangible assets, net 6,817,855 7,628,394
Goodwill 10,513,371 10,513,371
Other assets 1,674,251 2,113,147
Total assets 158,853,213 173,707,166
Current liabilities:    
Accounts payable and accrued expenses 16,477,761 19,597,787
Accounts payable and accrued expenses due to affiliated entity 847,421 1,072,579
Accrued clinical trial expenses 7,188,751 6,368,389
Common stock warrants 1,363,637 1,167,614
Deferred revenue 548,690 14,762,720
Deferred revenue from affiliated entity 274,194 407,292
Deferred rent 681,544 446,646
Total current liabilities 27,381,998 43,823,027
Deferred revenue, net of current portion 205,938 317,808
Deferred revenue from affiliated entity, net of current portion 0 86,694
Deferred rent, net of current portion 7,560,867 5,926,424
Deferred tax liabilities 174,793 174,793
Total liabilities 35,323,596 50,328,746
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock 0 0
Common stock 77,634 74,062
Additional paid-in capital 589,890,620 556,718,356
Accumulated deficit (467,715,568) (434,838,235)
Accumulated other comprehensive income 1,180,662 1,327,968
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 123,433,348 123,282,151
Non-controlling interest 96,269 96,269
Total stockholders’ equity 123,529,617 123,378,420
Total liabilities and stockholders’ equity $ 158,853,213 $ 173,707,166